Patrick Burnett Sells 3,675 Shares of Arcutis Biotherapeutics (NASDAQ:ARQT) Stock

Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) insider Patrick Burnett sold 3,675 shares of the stock in a transaction on Monday, February 2nd. The stock was sold at an average price of $25.50, for a total value of $93,712.50. Following the sale, the insider owned 90,445 shares in the company, valued at approximately $2,306,347.50. This represents a 3.90% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

Patrick Burnett also recently made the following trade(s):

• On Wednesday, February 4th, Patrick Burnett sold 9,794 shares of Arcutis Biotherapeutics stock. The stock was sold at an average price of $25.81, for a total value of $252,783.14.
• On Monday, January 5th, Patrick Burnett sold 2,490 shares of Arcutis Biotherapeutics stock. The shares were sold at an average price of $28.98, for a total value of $72,160.20.
• On Wednesday, December 31st, Patrick Burnett sold 1,697 shares of Arcutis Biotherapeutics stock. The shares were sold at an average price of $29.20, for a total value of $49,552.40.
• On Monday, December 15th, Patrick Burnett sold 11,500 shares of Arcutis Biotherapeutics stock. The stock was sold at an average price of $28.94, for a total transaction of $332,810.00.
• On Thursday, November 6th, Patrick Burnett sold 17,250 shares of Arcutis Biotherapeutics stock. The shares were sold at an average price of $24.18, for a total transaction of $417,105.00.

Arcutis Biotherapeutics Stock Performance

Arcutis Biotherapeutics stock opened at $26.07 on Friday. The firm’s 50 day simple moving average is $28.13 and its 200 day simple moving average is $22.46. The company has a current ratio of 3.50, a quick ratio of 3.28 and a debt-to-equity ratio of 0.68. The firm has a market capitalization of $3.19 billion, a PE ratio of -72.42 and a beta of 1.70. Arcutis Biotherapeutics, Inc. has a 1-year low of $11.13 and a 1-year high of $31.77.

Hedge Funds Weigh In On Arcutis Biotherapeutics

Several institutional investors have recently modified their holdings of the company. Johnson Investment Counsel Inc. bought a new stake in Arcutis Biotherapeutics in the 3rd quarter worth approximately $30,000. SBI Securities Co. Ltd. raised its stake in shares of Arcutis Biotherapeutics by 325.4% during the fourth quarter. SBI Securities Co. Ltd. now owns 1,089 shares of the company’s stock worth $32,000 after acquiring an additional 833 shares in the last quarter. PNC Financial Services Group Inc. lifted its holdings in shares of Arcutis Biotherapeutics by 10.2% in the 2nd quarter. PNC Financial Services Group Inc. now owns 8,828 shares of the company’s stock worth $124,000 after acquiring an additional 820 shares during the last quarter. Jones Financial Companies Lllp lifted its holdings in shares of Arcutis Biotherapeutics by 1,291.1% in the 3rd quarter. Jones Financial Companies Lllp now owns 7,067 shares of the company’s stock worth $124,000 after acquiring an additional 6,559 shares during the last quarter. Finally, Atlas Wealth LLC purchased a new stake in shares of Arcutis Biotherapeutics in the 2nd quarter valued at $138,000.

Wall Street Analyst Weigh In

ARQT has been the subject of several research analyst reports. The Goldman Sachs Group lifted their price objective on Arcutis Biotherapeutics from $19.00 to $29.00 and gave the company a “neutral” rating in a research note on Thursday, October 30th. HC Wainwright reaffirmed a “buy” rating and issued a $30.00 price target on shares of Arcutis Biotherapeutics in a report on Wednesday, October 29th. Zacks Research downgraded Arcutis Biotherapeutics from a “strong-buy” rating to a “hold” rating in a research report on Monday, December 29th. Wall Street Zen lowered Arcutis Biotherapeutics from a “strong-buy” rating to a “buy” rating in a report on Friday, January 23rd. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Arcutis Biotherapeutics in a research note on Monday, December 29th. Six research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $29.20.

More Arcutis Biotherapeutics News

Here are the key news stories impacting Arcutis Biotherapeutics this week:

• Positive Sentiment: Analyst support remains constructive — multiple firms maintain Buy/outperform views and the consensus rating sits at a “Moderate Buy” with an average price target near $29.20, which can limit downside pressure. Read More.
• Positive Sentiment: Several institutional investors added or initiated positions in Q4 (examples: Independent Advisor Alliance, Virginia Retirement Systems, Trek Financial, RFG Advisory), indicating fresh demand from funds that could support the stock. Read More.
• Neutral Sentiment: Arcutis granted 94,000 restricted stock units to 12 newly hired employees under a Nasdaq inducement rule — a sign of hiring/expansion but also a small potential dilution source; impact is likely minor. Read More.
• Neutral Sentiment: Reported short-interest data appears anomalous (effectively zero in recent reporting) and is unlikely to be a meaningful immediate catalyst; treat the reading with caution. Read More.
• Negative Sentiment: Clustered insider selling — multiple executives and a director disclosed sales on Feb. 2–4, totaling sizeable transactions and >$1M in proceeds. Notable filings include Masaru Matsuda (40,638 shares at ~$25.28), Todd Watanabe (19,833 at ~$25.50), Director Howard Welgus (10,000 at ~$25.05) and CFO Latha Vairavan (1,320 at ~$25.50). Concentrated insider sales can amplify short-term negative sentiment and weigh on the stock. Read More.

About Arcutis Biotherapeutics

Arcutis Biotherapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for immuno-inflammatory skin diseases. The company’s research and development efforts center on targeted treatments that address the underlying biology of conditions such as plaque psoriasis, atopic dermatitis, seborrheic dermatitis and vitiligo. Arcutis employs a precision-medicine approach to deliver topical therapies designed to improve efficacy and tolerability compared with existing treatment options.

In August 2022, Arcutis received U.S.